A daily multivitamin taken over two years slowed the pace of certain molecular aging markers in older adults, according to a new analysis from one of the largest randomized supplement trials ever conducted. The findings, drawn from 958 participants with an average age of about 70, add randomized evidence that a common over-the-counter multivitamin can measurably affect some epigenetic clocks, the DNA-based tools scientists use to estimate biological age. Yet the results come with a significant caveat: no one has shown that shifting these molecular markers actually translates into longer life or fewer diseases.
What the COSMOS Trial Measured
The epigenetic aging analysis is an ancillary study nested inside COSMOS, a large-scale randomized trial that enrolled 21,442 U.S. adults to test two interventions: cocoa extract and a daily multivitamin. The trial used a 2×2 factorial, double-blind, placebo-controlled design, and the multivitamin formulation was Centrum Silver, not a custom research product. That detail matters because it means the supplement tested is widely available and relatively inexpensive, making the results directly relevant to consumers who already take a similar pill.
For the aging substudy, researchers collected blood samples from 958 participants at three time points: baseline, year one, and year two. They then analyzed DNA methylation patterns, chemical tags on DNA that change predictably with age, to calculate several epigenetic clock scores. The key finding, described in a Nature Medicine report, was a statistically significant difference between the multivitamin and placebo groups on two second-generation epigenetic clocks. One of those clocks, PCGrimAge, showed a modest between-group difference (about 0.1 years per year) favoring the supplement group relative to placebo, indicating a small shift in that clock’s estimated aging trajectory over time.
To ensure that any observed differences were not just random noise, the investigators adjusted for baseline characteristics and used repeated measures over the two-year period. The consistency of the effect across time points on specific clocks, but not all of them, suggests a targeted rather than global shift in methylation patterns. Still, the magnitude of the change was modest, and the study was not powered to link those molecular shifts directly to clinical outcomes such as heart attacks or cancer diagnoses.
Epigenetic Clocks Are Promising but Unproven Proxies
The excitement around these findings rests on a technology that is still earning its credibility. Epigenetic clocks estimate biological age by reading patterns of DNA methylation across hundreds of genomic sites. Second-generation clocks like GrimAge and PhenoAge were trained not just on chronological age but on mortality risk and disease-related biomarkers, which is why shifts in their readings attract attention from aging researchers. A slower clock, in theory, signals a body that is aging more gradually at the molecular level.
But theory and proof are not the same thing. An expert commentary accompanying the multivitamin study flagged the gap between moving a molecular needle and delivering a clinical benefit. Epigenetic clocks have not yet been validated as surrogate endpoints in the way that, say, blood pressure readings stand in for stroke risk. A 0.1-year annual slowdown is statistically detectable in a controlled trial, yet its practical meaning for any individual remains unclear. The commentary also raised concerns about generalizability and the risk of over-interpreting results from a single trial cohort.
This distinction is easy to lose in popular coverage, where “slows aging” can quickly become “makes you younger.” The data support a narrower claim: among older adults who took Centrum Silver daily for two years, certain molecular markers moved in a direction associated with slower aging. Whether that movement corresponds to fewer heart attacks, less dementia, or more years of healthy life is a question the trial was not designed to answer. Longer follow-up of the COSMOS participants will be needed to see whether the modest clock changes foreshadow any divergence in real-world health outcomes.
Cognitive Gains from the Same Trial Platform
The epigenetic findings do not exist in isolation. COSMOS has generated several ancillary studies examining cognition, and their results add context to the aging data. A separate randomized analysis known as COSMOS-Web found that multivitamin use was associated with modest improvements in memory after one year, with sustained benefit averaged over three years. That study also confirmed, through biomarker checks in a subset of participants, that the multivitamin group had higher blood levels of folate, vitamin B12, and 25-hydroxyvitamin D compared to placebo, evidence that the pills were actually changing participants’ nutritional status.
A third analysis, the COSMOS-Clinic substudy, used in-person cognitive assessments rather than online tests. A meta-analysis of COSMOS cognition data pooled results across three related studies and reinforced the pattern of modest cognitive benefit. Taken together, these findings suggest the multivitamin is doing something measurable in the body and brain, even if the mechanism linking nutrient repletion to epigenetic clock changes remains speculative.
One plausible connection runs through micronutrient deficiency. Many older adults fall short on B vitamins, vitamin D, and other nutrients involved in DNA methylation and repair. If a daily multivitamin corrects those shortfalls, the downstream effects on methylation patterns could explain the clock changes without requiring any exotic anti-aging mechanism. That interpretation is more mundane than headlines suggest, but it is also more actionable: it implies the benefit may be largest for people whose diets are already lacking, rather than for well-nourished individuals looking for an extra edge.
What the Study Cannot Tell Us
Several gaps limit how far these results can travel. The COSMOS cohort was drawn from U.S. adults, and the available reporting does not provide detailed demographic breakdowns by race, ethnicity, or socioeconomic status for the epigenetic substudy. Aging biology varies across populations, and a finding in one group does not automatically apply to another. The trial also lasted only two years for the methylation measurements, a short window in the context of aging research where meaningful health divergence between groups may take a decade or more to appear.
There is also the question of whether the trial participants are representative of the broader older adult population. People who volunteer for long-term supplement studies may be more health-conscious, adhere better to medication schedules, and differ in unmeasured ways from those who do not enroll. Such selection factors can affect both baseline biological aging and responsiveness to interventions, making it risky to assume that similar epigenetic effects would appear in other groups without direct testing.
Another limitation is that the study cannot disentangle which specific components of the multivitamin are driving the observed changes. Centrum Silver contains a blend of vitamins and minerals at doses tailored for older adults. If only a subset of those ingredients is responsible for the epigenetic signal or the cognitive gains, a more targeted regimen might achieve similar benefits with fewer pills. Conversely, the combined formulation could be important if multiple nutrients work together on methylation pathways or brain function.
How Consumers Should Interpret the Findings
For individuals already taking a daily multivitamin, the COSMOS results offer a measure of reassurance: in a large randomized setting, the supplement was associated with modest shifts in certain molecular aging markers and small improvements on memory measures in ancillary studies. At the same time, the findings fall short of justifying multivitamins as anti-aging drugs. The changes in epigenetic clocks are incremental, and their link to tangible health outcomes remains unproven.
For those considering starting a multivitamin, the study underscores the importance of expectations. A pill that slightly slows an epigenetic clock is not a substitute for established health behaviors such as regular exercise, not smoking, and managing blood pressure and cholesterol. Instead, multivitamins may be best viewed as a nutritional safety net for older adults who struggle to meet recommended intakes from food alone, particularly for nutrients tied to methylation and brain health.
Future research will need to address several open questions: whether similar epigenetic effects appear in younger adults or non-U.S. populations; whether longer supplementation produces larger or more durable changes; and, most crucially, whether those molecular shifts predict differences in disease incidence, disability, or mortality. Until then, the COSMOS epigenetic analysis is an intriguing proof of concept rather than a prescription for longevity.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
